Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL). The most common side effects include serious infections, low blood cell counts and a weakened immune system. The most common side effects for the treatment of ALL include fever, CRS, hypotension, encephalopathy, tachycardias, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage |
|
sameAs | |
dbp:wikiPageUsesTemplate | |
ATC prefix |
|
DrugBank |
|
KEGG |
|
legal US |
|
pregnancy category |
|
routes of administration | |
synonyms |
|
tradename |
|
UNII |
|
has abstract |
|
DailyMedID |
|
legal CA |
|
legal EU |
|
licence US |
|
pregnancy AU |
|
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
alternative name |
|
DrugBank |
|
FDA UNII code |
|
KEGG |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |